Business
Immunome Appoints Kinney Horn as Chief Business Officer
BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted
About this update from Immunome, Inc.
[{"type":"text","content":" BOTHELL, Wash.--(BUSINESS WIRE)--\nImmunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate and business development, alliance management, and commercial strategy.\n\n\n“Immunome is excited to welcome Kinney to our executive team as we advance our broad pipeline of targeted therapies,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. “With the recent acquisition of AL102, Immunome is now a clinical stage company, and Kinney’s expertise in navigating the complex business landscape of biotechnology and his successful track record in forging strategic partnerships will be crucial as we expand our portfolio and enhance our development capabilities.”\n\n\n“I am thrilled to join Immunome at such a transformative time,” remarked Mr. Horn. “The opportunity to drive strategic business initiatives and expand Immunome’s strong portfolio is incredibly compelling. I look forward to working closely with Clay and the talented team at Immunome to make a meaningful impact on the lives of cancer patients.”\n\n\nPrior to joining Immunome, Mr. Horn was Chief Business Officer of Olema Oncology. In that role, he played an integral role in raising over $300M in capital, building the company, and expanding its pipeline through strategic transactions including the collaboration with Aurigene that produced the Company’s KAT6 program. Before Olema, he was an Entrepreneur in Residence at EcoR1 Capital.\n\n\nMr. Horn spent 16 years at Genentech, identifying both preclinical and clinical stage business development opportunities, structuring strategic alliances, and negotiating deals. During his time at Genentech, Mr. Horn closed numerous transactions and managed contractual relationships representing over $30B in value. Prior to Roche’s acquisition of Genentech, Mr. Horn also worked with early-stage biotechnology companies that Genentech invested in through GenenFUND, Genentech’s private equity fund. He began his career in various investment banking and venture roles.\n\n\nMr. Horn has degrees in economics, international affairs and biochemistry from Mary Washington College and Georgetown University....